Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)
Closed Posted
- Opportunity number
- PAR-25-107
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
-
- 93.121 Oral Diseases and Disorders Research
- 93.395 Cancer Treatment Research
- 93.396 Cancer Biology Research
- Funding instrument
- Grant
- Categories
-
- Education
- Health
- Eligible applicants
-
- State Governments
- Other
- Tribal Governments (Federally Recognized)
- Tribal Organizations (Not Federally Recognized)
- Non-501(c)(3) Nonprofits
- Independent School Districts
- Special District Governments
- Higher Education Inst. (Private)
- Public or Indian Housing Auth.
- County Governments
- City/Township Governments
- 501(c)(3) Nonprofits
- Small Businesses
- Higher Education Inst. (Public)
- For Profit Organizations
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
This Federal Grant Opportunity, issued by the National Cancer Institute (NCI), seeks grant applications to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system. The goal is to explore the clinical potential of these microorganisms for cancer imaging, therapeutics, or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles. This funding opportunity supports basic mechanistic and preclinical studies in cell culture and animal models. Eligible applicants include tribal governments, higher education institutions, small businesses, nonprofits, and others. The application deadline is May 7, 2025.
The funding for this opportunity is provided under CFDA numbers 93.395 Cancer Treatment Research, 93.121 Oral Diseases and Disorders Research, and 93.396 Cancer Biology Research, with typical award values ranging from $200,000 to over $1 million. The research activities are expected to be conducted at the applicant organizations' facilities across the United States.
Synopsis
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This NOFO will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis. This funding opportunity is part of broader NCI-sponsored research on microbial-based cancer therapy. (link to OCCAM)
Files
| File | Type | Posted |
|---|---|---|
| PAR-25-107-Full-Announcement.html | HTML file |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity